Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw an upside of 1.56% to close Tuesday at $9.78 after adding $0.15 on the day. The 5-day average trading volume is 16,489,119 shares of the company’s common stock. It has gained $9.99 in the past week and touched a new high 3 times within the past 5 days. An average of 11,754,815 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 12,599,594.
TEVA’s 1-month performance is 23.80% or $1.82 on its low of $7.80 reached on 07/10/23. The company’s shares have touched a 52-week low of $7.09 and high of $11.44, with the stock’s rally to the 52-week high happening on 01/12/23. YTD, TEVA has achieved 7.24% or $0.66 and has reached a new high 5 times. However, the current price is down -14.55% from the 52-week high price.
Insider Transactions
TEVA stock investors last saw insider trading activity on Aug 04. Weiss Amir (Chief Accounting Officer) most recently sold 1,981 shares at $9.92 per share on Aug 04. This transaction cost the insider $19,658. Hughes Eric A, sold 52,742 shares at a price of $8.30 on Aug 01. Then, on Mar 07, EVP, North America Commercial Dethlefs Sven sold 58,066 shares at a price of $9.43 per share. This transaction amounted to $547,440.
Valuation Metrics
TEVA stock has a beta of 1.18. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.70 while the price-to-book (PB) in the most recent quarter is 1.55, with the price to cash flow ratio at 8.93.
Teva Pharmaceutical Industries Limited’s quick ratio for the period ended June 29 was 0.70, with the current ratio over the same period at 1.00. As well, the company’s long term debt to equity for the quarter ending June 29 was 2.65, while the total debt to equity was 2.93.. In terms of profitability, the gross margin trailing 12 months is 49.10%. The trailing 12-month EBITDA margin is 26.73% while for the period ending June 29, Teva Pharmaceutical Industries Limited’s operating margin was -7.20%. The firm’s gross profit as reported stood at $6.97 billion against revenue of $14.93 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 73.12% to -$863.0 million, while revenue of -$205.0 million was 76.25% off the previous quarter. Analysts expected TEVA to announce $0.52 per share in earnings in its latest quarter, but it posted $0.56, representing a 7.70% surprise. EBITDA for the quarter stood at more than -$346.0 million. TEVA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 35.39 billion, with total debt at $21.02 billion. Shareholders hold equity totaling $1.12 billion.
Let’s look briefly at Teva Pharmaceutical Industries Limited (TEVA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 76.62% to suggest the stock is trending Overbought, with historical volatility in this time period at 61.28%.
The stock’s 5-day moving average is $9.60, reflecting a +17.97% or $1.49 change from its current price. TEVA is currently trading +20.30% above its 20-day SMA, +12.80% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +33.42% and SMA200 by+21.19%.
Stochastic %K and %D was 85.34% and 88.09% and the average true range (ATR) pointed at 0.35. The RSI (14) points at 73.93%, while the 14-day stochastic is at 87.96% with the period’s ATR at 0.32. The stock’s 9-day MACD Oscillator is pointing at 0.65 and 0.85 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Teva Pharmaceutical Industries Limited (NYSE: TEVA), UBS upgraded it to a Neutral rating. They previously had a Sell rating on the stock. Analysts offering their rating for TEVA stock have a consensus rating for the stock as Hold. Currently, 2 brokerage advisors rate TEVA as a “sell,”, while 8 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 3 have offered a “buy” rating.
What is TEVA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $8.00 and a high of $14.00, with their median price target at $10.00. Looking at these predictions, the average price target given by analysts is for Teva Pharmaceutical Industries Limited (TEVA) stock is $10.25.
